Expert Opinion: Professor Nick Lemoine on pancreatic cancer

Pancreatic cancer continues to be one of the hardest cancers to treat, so as part of our Research Strategy, we’ve pledged to boost research in this area with the ultimate aim of improving patients’ survival.

Professor Nick Lemoine, Director of the Barts Cancer Institute, is a world-leading expert in pancreatic cancer and as part of our ongoing Expert Opinion series, he shares his vision for a future in which we can beat this disease.

Professor Nick Lemoine

Professor Nick Lemoine is looking for new ways to detect and treat pancreatic cancer

Cancer Research UK: Why did you choose to focus on pancreatic cancer?

Nick Lemoine: It is a serious health problem across the western world and is becoming an increasing problem worldwide as we get more industrialised and people live longer.

Sadly, the 5-year survival rate hasn’t changed for the last 40 years, and that’s something that urgently needs addressing.

Cancer Research UK: What makes pancreatic cancer so difficult to treat?

Nick Lemoine: One significant problem with the pancreas is that it is deep within the body. You can’t see it, you can’t feel it and by the time symptoms or signs of the disease develop, surgery is no longer an option. And unfortunately, conventional chemotherapy drugs, which have largely been developed for other types of cancer, aren’t very effective, and neither is radiotherapy. So we need a new approach to the problem.

Continue reading

Expert Opinion: Dr Des Powe

Pills
Dr Des Powe wants to find out whether beta blockers could be used to treat cancer.

Can you teach an old drug new tricks? Thanks to a project grant from our Population Research Committee, Dr Des Powe hopes to find out.

Cancer cells have a tendency to spread (or metastasise) to other sites in the body, forming secondary tumours. Once this has happened, the disease can be difficult to treat. In the next in our series of Expert Opinion interviews, Dr Powe discusses his plans to find out whether a common drug could stop cancer in its tracks.

Cancer Research UK: Why are you so interested in breast cancer spread?

Des Powe: Around a third of breast cancer patients develop metastasis but those patients account for 90 per cent of breast cancer-associated deaths. So, if you can stop the cancer spreading in the first place, you could save the majority of those patients from dying and improve their quality of life in the process. And really that’s what my study is about.
Continue reading

EGFR – Wanna be starting something?

This entry is part 5 of 12 in our High-impact science series
Dr Julian Downward

Dr Julian Downward’s work in the 1980s paved the way for several targeted cancer treatments used today.

For many, the 1980s represent social unrest and wardrobe disasters. But amidst the strikes and the legwarmers, the 1980s gave us much to be thankful for. For cancer scientists, it was a Renaissance period – a decade during which cancer research came of age and (unlike many of us) got a proper haircut.

Cancer Research UK was at the heart of this maturation, so as part of our High-Impact Science series, we thought we’d go back and revisit a discovery that not only spawned a whole new field of cancer research, but led directly to the development of drugs that are used to treat cancer patients today.

Continue reading

Breast cancer and the neighbourhood watch

Bonnie and Clyde

IL-25 and its receptor are like a molecular Bonnie and Clyde

Scientists are constantly asking why so many of us get cancer, but perhaps an equally interesting question is why so many of us don’t.

Every single day, the DNA in our cells comes under constant attack – partly from toxins and radiation in our environment, but more regularly from the by-products of chemical reactions that keep us alive.

This means that we generate tumour-prone cells on a daily basis. So how do our bodies prevent these from developing into cancer?

Continue reading